Time to Go Shopping for Healthcare
The decline in equity markets has created opportunities to buy a variety of healthcare stocks at attractive valuations. Insider purchases have...
395 Views
Simcere Pharma (2096 HK): Sturdy 2025; Promising Pipeline, Approvals Will Take It Forward
​Simcere Pharma sees strong revenue growth driven by innovative products. Sanbexin injection increase market share in stroke treatment. Extensive...
267 Views
Shanghai Henlius (2696 HK): Innovative Portfolio Carry 2025 Along, Globalization Strategy On Track
​Shanghai Henlius saw robust revenue growth in 2025 driven by key products, despite rising expenses. Aiming for sustainable revenue through...
210 Views
Who's Optimistic About Pharmacy's Future in China? China Nepstar's Controlling Shareholder
China Nepstar's Chairman and his China Neptunus Drugstore Holding Ltd. (54% owner) has offered $2.60/ADS to take the company private (announcement...
577 Views
China ADR Privatizations: The Challenges of Getting the Best Deal
The stellar performance of China’s stock markets over the past twelve months (Shanghai +121%, Shenzhen +161%, and Hong Kong +17%) has led to a...
603 Views